骨髓增生异常综合征患者的间充质干细胞具有免疫抑制作用

Bone Marrow Mesenchymal Stem Cells Derived from Patients with Myelodysplastic Syndrome Possess Immunosuppressive Activity

本研究探讨骨髓增生异常综合征(MDS)患者间充质干细胞(MSC)的免疫抑制作用。采集MDS患者的骨髓标本,分离、培养和扩增MSC,观察细胞形态并进行表型鉴定;将不同数量的细胞加入单相混合淋巴细胞反应(MLR),检测MSC对自体及采自健康供者的异体外周血淋巴细胞(PBL)增殖水平的影响。结果发现:3×103-1×105个源于MDS患者的MSC可将自体PBL的增殖抑制到最大反应的(66.9±20.1)% -(30.2±5.9)%,将异体PBL的增殖抑制到最大反应的(56.6±14.7)% -(20.5±9.7)%,与培养自健康供者MSC的抑制作用相比,差异无统计学意义(P>0.05)。结论: MDS患者的MSC和健康者的MSC具有相似的免疫抑制功能。

This study was aimed to evaluate whether mesenchymal stem cells （MSCs） obtained from patients with myelodysplastic syndrome possess immunosuppressive effect, MSCs from bone marrow samples of MDS patients were isolated, cultured and expanded. MSCs were morphologically analyzed and their immunophenotype were determined by flow cycometry. Various amounts of MSCs were added into one-way mixed lymphocyte reaction, MSCs from MDS patients were tested for their ability to suppress in vitro proliferation of autologous and allogeneic peripheral blood lymphocytes （PBLs）. The results showed that 3 × 10^3 - 1 × 10^5 MSCs from MDS patients could inhibit autologuous PBLs proliferation to （66. 9 ± 20. 1 ） % - （ 30.2 ± 5.9 ） % of maximal response, as well as inhibit allogeneic PBLs proliferation to （56.6 ± 14.7 ）% - （20.5% ± 9.7 ）% of maximal response, as compared with inhibitory ability of MSCs from healthy donors, there was no significant difference （P 〉0.05）. It is concluded MSCs from patients with myelodysplastic syndrome also possess immunosuppressive activity.